Nurix–Roche BTK Degrader Deal Closes

Company Nurix Therapeutics / Roche Event Type Collaboration Closing (Deal & Financing) Modality Targeted Protein Degradation (BTK Degrader) Asset Bexobrutideg (NX-5948) Target BTK (Bruton’s Tyrosine Kinase) Disease Area Chronic Lymphocytic Leukemia / B-Cell Malignancies Summary Nurix and Roche closed their global bexobrutideg collaboration after the…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

YolTech – In Vivo CRISPR/Base Editing Platform Financing
Novartis Acquires Myricx Bio | Next-Generation ADC Payload Platform
Terremoto – $108M Series C Degrader Platform
Nurix–Roche BTK Degrader Deal Closes